Trial Outcomes & Findings for A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) (NCT NCT04172675)

Last Updated: 2025-08-01

Results Overview

RFS was defined as the time from the date of randomization until the date of the reappearance of high-risk disease (high-grade Ta, T1 or carcinoma in situ \[CIS\]), or death, whichever was reported first. Recurrence was assessed using cystoscopy, bladder mapping, urine cytology, and computed tomography (CT)/ magnetic resonance imaging (MRI) urogram. Participants who were recurrence-free and alive or had unknown status were censored at the last tumor assessment. The Kaplan-Meier method was used to estimate the distribution of overall RFS for each treatment group.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

107 participants

Primary outcome timeframe

From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months

Results posted on

2025-08-01

Participant Flow

Results are presented till final database lock date of 07 August 2024. Cohort 2 and Cohort 3 participants were involved in exploratory efficacy endpoints analysis and thus no efficacy data were reported in outcome measures section for Cohort 2 and 3. With implementation of Protocol Amendment 6 (dated 13 July 2023), long term extension (LTE) phase was added in study.

Participant milestones

Participant milestones
Measure	Cohort 1: Erdafitinib Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Overall Study STARTED	49	24	16	18
Overall Study Participants of Cohort 1: Investigator's Choice Crossed Over to Cohort 1 Erdafitinib	0	9	0	0
Overall Study Treated	49	23	16	18
Overall Study COMPLETED	42	19	15	14
Overall Study NOT COMPLETED	7	5	1	4

Reasons for withdrawal

Reasons for withdrawal
Measure	Cohort 1: Erdafitinib Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Overall Study Withdrawal by Subject	7	5	1	4

Baseline Characteristics

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cohort 1: Erdafitinib n=49 Participants Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice n=24 Participants Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib n=16 Participants Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib n=18 Participants Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Total n=107 Participants Total of all reporting groups
Age, Continuous	68.3 Years STANDARD_DEVIATION 10.89 • n=5 Participants	67 Years STANDARD_DEVIATION 11.3 • n=7 Participants	66.7 Years STANDARD_DEVIATION 12.37 • n=5 Participants	61.6 Years STANDARD_DEVIATION 9.05 • n=4 Participants	66.6 Years STANDARD_DEVIATION 11.04 • n=21 Participants
Sex: Female, Male Female	12 Participants n=5 Participants	5 Participants n=7 Participants	2 Participants n=5 Participants	9 Participants n=4 Participants	28 Participants n=21 Participants
Sex: Female, Male Male	37 Participants n=5 Participants	19 Participants n=7 Participants	14 Participants n=5 Participants	9 Participants n=4 Participants	79 Participants n=21 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	9 Participants n=5 Participants	5 Participants n=7 Participants	2 Participants n=5 Participants	3 Participants n=4 Participants	19 Participants n=21 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	32 Participants n=5 Participants	15 Participants n=7 Participants	11 Participants n=5 Participants	12 Participants n=4 Participants	70 Participants n=21 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	8 Participants n=5 Participants	4 Participants n=7 Participants	3 Participants n=5 Participants	3 Participants n=4 Participants	18 Participants n=21 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Asian	14 Participants n=5 Participants	7 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	25 Participants n=21 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	3 Participants n=21 Participants
Race (NIH/OMB) White	27 Participants n=5 Participants	12 Participants n=7 Participants	9 Participants n=5 Participants	15 Participants n=4 Participants	63 Participants n=21 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants
Race (NIH/OMB) Unknown or Not Reported	7 Participants n=5 Participants	4 Participants n=7 Participants	3 Participants n=5 Participants	2 Participants n=4 Participants	16 Participants n=21 Participants
Region of Enrollment Argentina	2 Participants n=5 Participants	3 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	8 Participants n=21 Participants
Region of Enrollment Australia	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Region of Enrollment Belgium	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants
Region of Enrollment Brazil	7 Participants n=5 Participants	3 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	11 Participants n=21 Participants
Region of Enrollment China	0 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants
Region of Enrollment France	5 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	12 Participants n=21 Participants
Region of Enrollment Germany	2 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	4 Participants n=21 Participants
Region of Enrollment India	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Region of Enrollment Italy	5 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	9 Participants n=21 Participants
Region of Enrollment Japan	6 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	0 Participants n=4 Participants	11 Participants n=21 Participants
Region of Enrollment Poland	2 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	4 Participants n=21 Participants
Region of Enrollment Korea, South	8 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	10 Participants n=21 Participants
Region of Enrollment Spain	2 Participants n=5 Participants	3 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	5 Participants n=21 Participants
Region of Enrollment United Kingdom	3 Participants n=5 Participants	0 Participants n=7 Participants	4 Participants n=5 Participants	3 Participants n=4 Participants	10 Participants n=21 Participants
Region of Enrollment United States	6 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	10 Participants n=4 Participants	17 Participants n=21 Participants

PRIMARY outcome

Timeframe: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months

Population: Intent-to-Treat (ITT) analysis set included all randomized participants. Participants in Cohort 1 were primarily analyzed by the treatment to which they were assigned, regardless of the actual treatment received. Data for this outcome measure was planned to be collected and analyzed for specified arms only as planned in protocol.

Outcome measures

Outcome measures
Measure	Cohort 1: Erdafitinib n=49 Participants Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice n=24 Participants Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Cohort 1: Recurrence-Free Survival (RFS)	NA Months Interval 28.58 to Here, 'NA' signifies that median and upper limit of 95 percent (%) confidence interval (CI) could not be calculated due to less number of participants with event.	11.60 Months Interval 5.29 to Here, 'NA' signifies that upper limit of 95% CI could not be calculated due to less number of participants with event.	—	—

SECONDARY outcome

Timeframe: At Month 6 and Month 12

Population: ITT analysis set included all randomized participants. Participants in Cohort 1 were primarily analyzed by the treatment to which they were assigned, regardless of the actual treatment received. Data for this outcome measure was planned to be collected and analyzed for specified arms only as planned in protocol.

RFS rate was the proportion of participants who were recurrence-free and alive based on Kaplan-Meier estimates. RFS was defined as the time from the date of randomization until the date of the reappearance of high-risk disease (high-grade Ta, T1 or CIS), or death, whichever was reported first. Recurrence was assessed using cystoscopy, bladder mapping, urine cytology, and CT/ MRI urogram. Participants who were recurrence-free and alive or had unknown status were censored at the last tumor assessment.

Outcome measures

Outcome measures
Measure	Cohort 1: Erdafitinib n=49 Participants Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice n=24 Participants Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Cohort 1: Recurrence-Free Survival Rate at 6 Months and 12 Months 6-month survival rate	0.96 Proportion of participants Interval 0.84 to 0.99	0.73 Proportion of participants Interval 0.49 to 0.87	—	—
Cohort 1: Recurrence-Free Survival Rate at 6 Months and 12 Months 12-month survival rate	0.79 Proportion of participants Interval 0.64 to 0.89	0.44 Proportion of participants Interval 0.22 to 0.63	—	—

SECONDARY outcome

Timeframe: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months

Time to progression (TTP) was defined as the time from the date of randomization until the date of first documented evidence of any of the following: disease progression (PD) or death. PD included development of or increase in stage to lamina propria invasion (for example- increase from Ta to T1), development of or increase in stage to muscle-invasive disease (stage greater than or equal to \[\>=\] T2), development of or increase in stage to lymph node (N+) or distant metastasis (M1) disease (participants must have previously been diagnosed with N0 and/or M0 disease), increase in tumor grade from low to high (including CIS).

Outcome measures

Outcome measures
Measure	Cohort 1: Erdafitinib n=49 Participants Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice n=24 Participants Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Cohort 1: Time to Progression	NA Months Here 'NA' signifies that median, lower and upper limit of 95% CI could not be calculated as there were small number of participants with events due to early termination of the participants enrollment.	NA Months Here 'NA' signifies that median, lower and upper limit of 95% CI could not be calculated as there were small number of participants with events due to early termination of the participants enrollment.	—	—

SECONDARY outcome

Timeframe: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months

Overall survival was defined as the time from the date of randomization to the date of the participant's death due to any cause.

Outcome measures

Outcome measures
Measure	Cohort 1: Erdafitinib n=49 Participants Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice n=24 Participants Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Cohort 1: Overall Survival	NA Months Here, 'NA' signifies that median, lower and upper limit of 95% CI could not be calculated as there were small number of participants with events due to early termination of the participants enrollment.	NA Months Here, 'NA' signifies that median, lower and upper limit of 95% CI could not be calculated as there were small number of participants with events due to early termination of the participants enrollment.	—	—

SECONDARY outcome

Timeframe: From start of treatment (Day 1) up to 25.2 months

Population: Safety analysis set included all participants who received at least 1 dose of study drug.

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were the events between first dose of study drug and up to 30 (+7 days) days after last dose or before start of subsequent anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure (OM).

Outcome measures

Outcome measures
Measure	Cohort 1: Erdafitinib n=49 Participants Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice n=23 Participants Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib n=16 Participants Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib n=18 Participants Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)	49 Participants	19 Participants	16 Participants	18 Participants

SECONDARY outcome

Timeframe: All cohorts: Pre-dose on Cycle 1 Day 14, pre-dose and 3 hours post-dose on Cycle 2 Day 1 (each cycle was of 28 days)

Population: Pharmacokinetic (PK) evaluable analysis set: all randomized (Cohort 1) or treated (Cohort 2 and 3) participants who had received at least 1 dose of erdafitinib and had at least 1 PK sample obtained post-treatment. 'N' (overall number of participants analyzed): number of participants evaluable for this OM, 'n' (number analyzed): participants analyzed at specified time points. Data for this outcome measure was not planned to be collected and analyzed for 'Cohort 1: Investigator's Choice' arm.

Plasma concentrations of erdafitinib were reported. Plasma samples were analyzed using liquid chromatography/mass spectrometry method.

Outcome measures

Outcome measures
Measure	Cohort 1: Erdafitinib n=43 Participants Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice n=16 Participants Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib n=18 Participants Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Plasma Concentrations of Erdafitinib Cycle 1 Day 14: Predose	592 Nanograms per milliliter (ng/mL) Standard Deviation 252	525 Nanograms per milliliter (ng/mL) Standard Deviation 227	605 Nanograms per milliliter (ng/mL) Standard Deviation 171	—
Plasma Concentrations of Erdafitinib Cycle 2 Day 1: Predose	635 Nanograms per milliliter (ng/mL) Standard Deviation 335	603 Nanograms per milliliter (ng/mL) Standard Deviation 350	685 Nanograms per milliliter (ng/mL) Standard Deviation 246	—
Plasma Concentrations of Erdafitinib Cycle 2 Day 1: 3 hours post dose	750 Nanograms per milliliter (ng/mL) Standard Deviation 367	739 Nanograms per milliliter (ng/mL) Standard Deviation 337	709 Nanograms per milliliter (ng/mL) Standard Deviation 220	—

Adverse Events

Cohort 1: Erdafitinib

Serious events: 13 serious events

Other events: 49 other events

Deaths: 5 deaths

Cohort 1: Investigator's Choice

Serious events: 2 serious events

Other events: 19 other events

Deaths: 0 deaths

Cohort 1: Crossover Participants From Investigator's Choice to Erdafitinib

Serious events: 3 serious events

Other events: 9 other events

Deaths: 0 deaths

Cohort 2: Erdafitinib

Serious events: 4 serious events

Other events: 16 other events

Deaths: 1 deaths

Cohort 3: Erdafitinib

Serious events: 1 serious events

Other events: 18 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Cohort 1: Erdafitinib n=49 participants at risk Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice n=23 participants at risk Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Crossover Participants From Investigator's Choice to Erdafitinib n=9 participants at risk Participants in Cohort 1 who initially received investigator's choice of treatment with locally confirmed high-risk recurrence on investigator's choice were offered an option to crossover at crossover screening visit and received erdafitinib tablets orally, at a dose of 6 mg once daily starting from crossover Cycle 1 Day 1 (Month 12) up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years) until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib n=16 participants at risk Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib n=18 participants at risk Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Eye disorders Cataract	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Central Serous Chorioretinopathy	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 2/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Detachment of Macular Retinal Pigment Epithelium	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Keratitis	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Maculopathy	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Colitis Ulcerative	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Diarrhoea	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Dry Mouth	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Gastritis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Pancreatitis	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Pyrexia	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Enterococcal Bacteraemia	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Pneumonia	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Pulmonary Sepsis	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Urinary Tract Infection	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Urosepsis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Brain Contusion	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Subdural Haemorrhage	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Osteoarthritis	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Spondylitis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon Cancer	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastric Cancer	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neuroendocrine Carcinoma of the Skin	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Nervous system disorders Syncope	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Acute Kidney Injury	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Hydronephrosis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Renal Colic	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Urinary Tract Obstruction	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Reproductive system and breast disorders Prostatitis	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Vascular disorders Hypotension	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Vascular disorders Peripheral Artery Occlusion	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.

Other adverse events

Other adverse events
Measure	Cohort 1: Erdafitinib n=49 participants at risk Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 milligrams (mg) once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Investigator's Choice n=23 participants at risk Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy and who either refused or were not eligible for cystectomy received the investigator's choice of treatment: either gemcitabine intravesical instillation (4 induction doses: 2000 mg once weekly on Days 1, 8, 15 and 22 of Cycle 1 followed by monthly maintenance dose on Day 1 of Cycle 2 to 7, each cycle of 28 days) or either mitomycin C (MMC) or hyperthermic MMC as an intravesical instillation at the dose of 40 mg/40 milliliter (mL). Additional doses of induction or maintenance were allowed per local standard of care. The choice of drug was determined by the investigator and treatment continued until its completion, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). Participants with locally confirmed high-risk recurrence on Investigator's Choice were offered an option to crossover treatment with erdafitinib until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 1: Crossover Participants From Investigator's Choice to Erdafitinib n=9 participants at risk Participants in Cohort 1 who initially received investigator's choice of treatment with locally confirmed high-risk recurrence on investigator's choice were offered an option to crossover at crossover screening visit and received erdafitinib tablets orally, at a dose of 6 mg once daily starting from crossover Cycle 1 Day 1 (Month 12) up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years) until protocol amendment 6 (dated 13 July 2023). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 2: Erdafitinib n=16 participants at risk Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor and who either refused or were not eligible for cystectomy received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.	Cohort 3: Erdafitinib n=18 participants at risk Participants with intermediate-risk NMIBC presenting as papillary disease only (low grade \[Grade 1- Grade 2\], Ta or T1, with no previous CIS) received erdafitinib tablets orally, at a dose of 6 mg once daily starting from Day 1 through Day 28 in each subsequent 28-day cycle starting from Day 1 of Cycle 1 up to disease recurrence or progression, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurred first (up to 2 years). With the implementation of Protocol Amendment 6 (dated 13 July 2023), participants who benefited from the study drug, as determined by investigator, continued to receive study drug in the LTE phase. The participants who did not enter LTE phase discontinued the study.
Blood and lymphatic system disorders Anaemia	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	8.7% 2/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Blood and lymphatic system disorders Thrombocytopenia	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Cardiac disorders Palpitations	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Congenital, familial and genetic disorders Corneal Dystrophy	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Ear and labyrinth disorders Tinnitus	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Ear and labyrinth disorders Tympanic Membrane Perforation	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Blepharitis	10.2% 5/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Cataract	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Cataract Subcapsular	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Central Serous Chorioretinopathy	22.4% 11/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	33.3% 3/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Corneal Scar	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Detachment of Retinal Pigment Epithelium	10.2% 5/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Dry Age-Related Macular Degeneration	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Dry Eye	22.4% 11/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	25.0% 4/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	27.8% 5/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Eye Discharge	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Eye Pain	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Eyelid Oedema	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Glaucoma	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Keratitis	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Keratopathy	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Lacrimation Increased	16.3% 8/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Metamorphopsia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Ocular Hyperaemia	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Optic Disc Disorder	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Photophobia	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Punctate Keratitis	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Retinal Detachment	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Retinal Dystrophy	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Retinal Exudates	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Retinal Vein Occlusion	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Retinopathy	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Serous Retinal Detachment	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Subretinal Fluid	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Subretinal Hyperreflective Exudation	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Swelling of Eyelid	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Ulcerative Keratitis	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Vision Blurred	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 4/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Visual Acuity Reduced	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Visual Impairment	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Vitreous Detachment	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Vitreous Floaters	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Eye disorders Xerophthalmia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Abdominal Distension	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Abdominal Pain	12.2% 6/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	27.8% 5/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Abdominal Pain Upper	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Chapped Lips	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Cheilitis	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Constipation	20.4% 10/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	31.2% 5/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	44.4% 8/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Diarrhoea	59.2% 29/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	13.0% 3/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	44.4% 4/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	56.2% 9/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	83.3% 15/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Dry Mouth	46.9% 23/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	66.7% 6/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	56.2% 9/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	72.2% 13/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Dyspepsia	14.3% 7/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 2/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 4/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Dysphagia	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Faecaloma	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Faeces Soft	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Gastritis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Gastrointestinal Disorder	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Gingival Pain	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Gingival Ulceration	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Glossitis	8.2% 4/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Haemorrhoids	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Hyperchlorhydria	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Lip Blister	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Lip Dry	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Lip Ulceration	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Mouth Ulceration	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Nausea	10.2% 5/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	27.8% 5/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Oral Dysaesthesia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Oral Pain	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Paraesthesia Oral	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Stomatitis	44.9% 22/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	33.3% 3/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	50.0% 8/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	27.8% 5/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Gastrointestinal disorders Vomiting	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Asthenia	10.2% 5/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 4/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Enanthema	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Fatigue	18.4% 9/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 2/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	38.9% 7/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Influenza Like Illness	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Mucosal Inflammation	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Non-Cardiac Chest Pain	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Oedema Peripheral	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	8.7% 2/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Pain	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Pyrexia	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
General disorders Temperature Intolerance	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Hepatobiliary disorders Cholelithiasis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Hepatobiliary disorders Hyperbilirubinaemia	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Immune system disorders Drug Hypersensitivity	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Balanitis Candida	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Candida Infection	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Conjunctivitis	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Covid-19	12.2% 6/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Cystitis	8.2% 4/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	8.7% 2/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Eye Infection	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Folliculitis	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Gastroenteritis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Influenza	8.2% 4/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Nail Infection	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Nasopharyngitis	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Oral Candidiasis	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Oral Fungal Infection	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Orchitis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Otitis Media	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Paronychia	16.3% 8/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 4/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Pneumonia	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Skin Infection	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Urinary Tract Infection	18.4% 9/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	13.0% 3/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 2/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	31.2% 5/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 4/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Infections and infestations Urinary Tract Infection Bacterial	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Arthropod Bite	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Injury Corneal	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Limb Injury	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Muscle Strain	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Post Procedural Haemorrhage	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Procedural Pain	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Skin Laceration	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Injury, poisoning and procedural complications Thermal Burn	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Alanine Aminotransferase Increased	12.2% 6/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	8.7% 2/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	31.2% 5/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	16.7% 3/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Aspartate Aminotransferase Increased	12.2% 6/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	13.0% 3/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	16.7% 3/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Blood Alkaline Phosphatase Increased	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Blood Calcium Increased	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Blood Creatinine Increased	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Blood Parathyroid Hormone Increased	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Blood Phosphorus Decreased	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Blood Phosphorus Increased	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Cardiac Murmur	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Gamma-Glutamyltransferase Increased	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Intraocular Pressure Increased	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Lipase Increased	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Ophthalmological Examination Abnormal	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Investigations Weight Decreased	14.3% 7/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	31.2% 5/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	27.8% 5/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Decreased Appetite	22.4% 11/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 2/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 4/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Dehydration	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hyperkalaemia	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hyperphosphataemia	73.5% 36/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	66.7% 6/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	56.2% 9/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	100.0% 18/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hyperphosphatasaemia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hypoalbuminaemia	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hypomagnesaemia	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hyponatraemia	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Metabolism and nutrition disorders Hypophosphataemia	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Arthralgia	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Back Pain	8.2% 4/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	8.7% 2/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Bone Swelling	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Bursitis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Exostosis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Groin Pain	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Muscle Spasms	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Myalgia	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Musculoskeletal and connective tissue disorders Pain in Extremity	8.2% 4/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Fibroma	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Nervous system disorders Ageusia	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Nervous system disorders Dizziness	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 2/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Nervous system disorders Dysgeusia	22.4% 11/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	43.8% 7/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	55.6% 10/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Nervous system disorders Headache	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	8.7% 2/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 4/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Nervous system disorders Memory Impairment	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Nervous system disorders Paraesthesia	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Nervous system disorders Peripheral Sensory Neuropathy	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Nervous system disorders Taste Disorder	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Psychiatric disorders Depressed Mood	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Psychiatric disorders Depression	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Psychiatric disorders Insomnia	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	25.0% 4/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Psychiatric disorders Libido Decreased	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Psychiatric disorders Sleep Disorder	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Acute Kidney Injury	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Bladder Spasm	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Chronic Kidney Disease	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	8.7% 2/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Dysuria	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	13.0% 3/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Haematuria	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	13.0% 3/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	25.0% 4/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Pollakiuria	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	8.7% 2/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Renal Impairment	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Renal and urinary disorders Strangury	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Reproductive system and breast disorders Cystocele	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Reproductive system and breast disorders Epididymal Cyst	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Reproductive system and breast disorders Genital Lesion	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Reproductive system and breast disorders Penile Erosion	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Reproductive system and breast disorders Scrotal Dermatitis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Reproductive system and breast disorders Testicular Atrophy	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Reproductive system and breast disorders Uterine Polyp	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Reproductive system and breast disorders Vaginal Discharge	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Cough	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	17.4% 4/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Dry Throat	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Dysphonia	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Epistaxis	14.3% 7/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 2/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 4/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Laryngeal Inflammation	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Nasal Dryness	8.2% 4/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	33.3% 6/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Nasal Obstruction	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Respiratory, thoracic and mediastinal disorders Sneezing	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Alopecia	20.4% 10/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 2/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	33.3% 6/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Blister	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Dermatitis Contact	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Dry Skin	24.5% 12/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	33.3% 3/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	43.8% 7/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	50.0% 9/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Eczema Asteatotic	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Erythema	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Hair Colour Changes	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Hair Texture Abnormal	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Hirsutism	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Hyperhidrosis	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Hyperkeratosis	10.2% 5/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Nail Bed Inflammation	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Nail Discolouration	10.2% 5/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 2/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 2/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Nail Disorder	14.3% 7/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	37.5% 6/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	27.8% 5/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Nail Dystrophy	32.7% 16/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	33.3% 3/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	22.2% 4/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Nail Hypertrophy	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Nail Toxicity	8.2% 4/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Onychalgia	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Onychoclasis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Onycholysis	20.4% 10/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	27.8% 5/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Onychomadesis	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	18.8% 3/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Palmar-Plantar Erythrodysaesthesia Syndrome	12.2% 6/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	31.2% 5/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	38.9% 7/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Pruritus	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Purpura	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Rash	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	25.0% 4/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Rash Macular	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Rash Maculo-Papular	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Rash Pruritic	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Skin Discolouration	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Skin Exfoliation	4.1% 2/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Skin Fissures	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	12.5% 2/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Skin and subcutaneous tissue disorders Skin Ulcer	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	6.2% 1/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Vascular disorders Hypertension	2.0% 1/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	4.3% 1/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	25.0% 4/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Vascular disorders Hypotension	6.1% 3/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Vascular disorders Superficial Vein Thrombosis	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	11.1% 1/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.
Vascular disorders Varicose Vein	0.00% 0/49 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/23 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/9 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	0.00% 0/16 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.	5.6% 1/18 • Cohort (C) 1 (Erdafitinib and Investigators Choice), C2 and C3: All cause mortality: From randomization (Cycle 1 Day 1, pre-dose) up to 48.2 months; Serious AEs/Other AEs: From start of treatment (Day 1 of Cycle 1) up to 30(+7 days) days after last dose (up to 25.2 months), C1 crossover participants: All cause mortality: Screening crossover visit (Month 12) up to 48.2 months; Serious AEs/Other AEs: Screening crossover visit (Month 12) up to 30(+7 days) days after last dose (up to 25.2 months) All cause mortality: analyzed on all randomized participants, Serious AEs (SAEs) and Other AEs: Safety analysis set included all participants who received at least 1 dose of study drug. AEs were collected and analyzed collectively in investigator's arm for gemcitabine or mitomycin C (MMC)/hyperthermic MMC. Per plan safety was analyzed per intervention.

Additional Information

Clinical Leader

Janssen Research & Development, LLC

Phone: 844-434-4210

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.
Publication restrictions are in place

Restriction type: OTHER